首页 Immunogen(usIMGN)-基本信息

Immunogen(usIMGN)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:7.85

最高价:7.85

成交量:1355136.0

昨收价:7.85

最低价:7.44

最新价:7.56

行情图标
概要信息

英文名称:Immunogen


行业:医疗


简介:ImmunoGen, Inc.于1981年在马萨诸塞州组成,专注于基于抗体的抗癌疗法的研发.该公司利用其专有的抗体药物共轭技术和ADC技术治疗癌症


电话:1-781-8950600


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

ImmunoGen免疫原公司是一家生物技术公司,开发有针对性的抗癌疗法,利用抗体-药物偶联技术开发产品,并通过抗体-药物偶联药物对HER2阳性转移性乳腺癌的进行治疗。另外,ImmunoGen还为罗氏提供Kadcyla特许权使用权(收取使用费)。ImmunoGen公司主要产品: IMGN853 - I期临床试验阶段,对卵巢癌,子宫内膜癌和其它癌症进行治疗 IMGN289 - I期临床试验阶段,对脑癌、肩颈癌以及非小细胞肺癌、鳞状细胞癌的治疗 IMGN529 - I期临床试验阶段,对淋巴瘤、慢性淋巴细胞白血病进行治疗 IMGN779 - 在临床前阶段,用于治疗急性髓细胞性白血病 AMG172 - I期临床试验阶段,肾透明细胞癌的治疗(化合物) AMG595 - I期临床试验阶段,用于治疗成胶质细胞瘤(化合物) BAY94-9343 - 早期临床阶段,用于间皮瘤和卵巢癌的治疗 BT-062 - 多发性骨髓瘤治疗 SAR3419 - II期临床试验,用于弥漫性大B细胞淋巴瘤的治疗 SAR650984 - 早期临床试验,用于治疗多发性骨髓瘤 SAR566658 - I期临床试验,用于治疗CA6阳性实体瘤 SAR408701 - 治疗固体肿瘤

交易日期 交易人 职位 类型 交易份额 价格
2019-06-30 Barrows (Craig) General Counsel Buy 5230 1.84
2019-06-30 Ryll (Thomas) Officer Buy 5230 1.84
2019-06-30 Berkenblit (Anna) Officer Buy 5230 1.84
2019-06-30 Mckee (Blaine H Ph.D.) Officer Buy 5230 1.84
2019-06-30 Foster David G Officer Buy 3536 1.84
2019-06-30 Enyedy (Mark J) Chief Executive Officer Buy 5230 1.84
2019-01-06 Gregory (Richard J) Officer Sell 3038 5.27
2019-01-02 Ryll (Thomas) Officer Buy 2455 4.08
2019-01-02 Enyedy (Mark J) Chief Executive Officer Buy 2455 4.08
2019-01-02 Foster David G Officer Buy 1472 4.08
2019-01-02 Barrows (Craig) General Counsel Buy 2455 4.08
2019-01-02 Berkenblit (Anna) Officer Buy 2455 4.08
2019-01-02 Wingrove Theresa G Officer Buy 2244 4.08
2018-11-05 Goldberg (Mark Alan) Director Buy 30000 5.76
2018-10-15 Berkenblit (Anna) Officer Sell 5851 8.00
2018-09-09 Berkenblit (Anna) Officer Sell 5851 9.46
2018-06-05 Johnston David Brannon Chief Financial Officer Buy 10000 3.05
2018-06-05 Johnston David Brannon Chief Financial Officer Sell 10000 11.02
2018-03-15 Junius (Daniel M) Director Sell 25000 12.02
2018-03-15 Junius (Daniel M) Director Buy 25000 4.29
2018-03-14 Johnston David Brannon Chief Financial Officer Sell 10000 11.53
2018-03-14 Johnston David Brannon Chief Financial Officer Buy 10000 3.05
2018-02-21 Ryll (Thomas) Officer Sell 11495 5.60
2018-02-21 Berkenblit (Anna) Officer Sell 16562 5.60
2018-02-21 Wingrove Theresa G Officer Sell 11032 5.60

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
FMR Inc 1696894 1.13% -4731090 -73.60% 2019-03-31
BlackRock Fund Advisors 6599563 4.40% 27931 0.43% 2019-07-31
Renaissance Technologies Corp 7043640 4.71% 861500 13.94% 2019-03-31
ClearBridge Advisors, LLC 8870628 5.93% 464147 5.52% 2019-03-31
SSGA Funds Management Inc 10228806 6.82% -11460 -0.11% 2019-07-31
Vanguard Group Inc 10529150 7.04% 36927 0.35% 2019-03-31
BlackRock Inc 12316896 8.24% -61308 -0.50% 2019-03-31
State Street Corporation 12647744 8.46% 4547373 56.14% 2019-03-31
Redmile Group, LLC 13063767 8.74% 2179160 20.02% 2019-03-31
PRIMECAP Management Company 3757600 2.51% -7400 -0.20% 2019-03-31
Morgan Stanley - Brokerage Accounts 3340830 2.23% -2019368 -37.67% 2019-03-31
Vanguard Investments Australia Ltd 3329732 2.22% 561489 20.28% 2019-07-31
Northern Trust Corp 1769126 1.18% -4647 -0.26% 2019-03-31
Northern Trust Investments N A 1769126 1.18% -4647 -0.26% 2019-03-31
Geode Capital Management, LLC 1864609 1.25% -1570931 -45.73% 2019-03-31
Bank of America Corporation 1870390 1.25% 1075483 135.30% 2019-03-31
Fidelity Management & Research Company 2022035 1.35% -2004634 -49.78% 2019-07-31
T. Rowe Price Associates, Inc. 2440764 1.63% 103471 4.43% 2019-03-31
ArrowMark Colorado Holdings, LLC (ArrowMark Partners) 2793351 1.87% -813373 -22.55% 2019-03-31
Northern Trust Investments Inc 2801556 1.87% 2214 0.08% 2019-07-31
Fidelity Management and Research Company 1696894 1.13% -4710690 -73.52% 2019-03-31
BlackRock Asset Management Canada Ltd 3356668 2.24% -135 -- 2019-05-31
Millennium Management LLC 4389260 2.94% 3552118 424.31% 2018-12-31
ING Investment Management LLC 2232721 1.49% -191296 -7.89% 2018-12-31
Point72 Asset Management, L.P. 2654299 1.78% -3518466 -57.00% 2018-12-31
Fidelity SelectCo, LLC 3905359 2.61% -1217659 -23.77% 2019-03-31
Citadel Advisors Llc 2305676 1.54% 437848 23.44% 2018-09-30
TIAA-CREF Investment Management LLC 2405904 1.61% 1210268 101.22% 2018-09-30
Teachers Advisors LLC 4890042 3.28% 2595252 113.09% 2018-09-30
Capital Research Global Investors 7095570 4.76% -2335430 -24.76% 2018-09-30
Capital Research and Management Company 6145570 4.12% -2335430 -27.54% 2018-12-31
Orbimed Advisors, LLC 2904270 1.95% 1400000 93.07% 2018-06-30
BlackRock Institutional Trust Company NA 3941530 2.64% 980855 33.13% 2018-06-30
State Street Corp 8996007 6.04% 1758759 24.30% 2018-06-30
Morgan Stanley & Co Inc 2709638 1.82% 1608293 146.03% 2018-06-30
Teachers Advisors Inc 2294790 1.54% 1133730 97.65% 2018-06-30
Franklin Advisers Inc 1737000 1.17% -935400 -35.00% 2018-06-30
Goldman, Sachs & Co. 1519235 1.02% 604541 66.09% 2018-06-30
Pinnacle Associates Inc 1267507 0.95% -54724 -4.14% 2018-03-31
Wells Fargo Advisors, LLC 1365331 1.03% -39627 -2.82% 2018-03-31
Delaware Management Business Trust 1130000 0.85% -- -- 2018-03-31
Baker Bros Advisors LP 2563489 1.93% -125000 -4.65% 2017-12-31
Morgan Stanley & Co International PLC 1142300 0.86% 1142300 -- 2017-12-31
Invesco PowerShares Capital Mgmt LLC 1058198 0.80% 583800 123.06% 2017-12-31
Fundlogic SAS 997645 0.75% 997645 -- 2017-12-31
Panagora Asset Management Inc 919509 0.80% -633629 -40.80% 2017-09-30
Morgan Stanley Smith Barney LLC 871348 0.75% -26570 -2.96% 2017-09-30
Delaware Management Company 1130000 0.85% -- -- 2018-01-31
Managed Account Advisors LLC 1689384 1.46% 564893 50.24% 2017-09-30
Close Finsbury Asset Management Limited 825929 0.93% 56581 7.35% 2017-10-31
Arrowstreet Capital Limited Partnership 817616 0.71% 803216 5577.89% 2017-09-30
Raymond James & Associates 657202 0.75% 10762 1.66% 2016-09-30
Deutsche Bank AG 1274733 1.46% 69507 5.77% 2016-09-30
The Vanguard Group 5310180 9.00% 74342520 0.10% 1999-11-30
BlackRock,Inc. 5960625 9.00% 83448750 0.10% 1999-11-30
FMR LLC 9416760 9.00% 131834640 0.10% 1999-11-30
ClearBridge Investments,LLC 13500010 9.00% 189000140 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fidelity 586584 0.39% 75568 14.79% 2019-04-30
Vanguard Strategic Equity Fund 1121434 0.75% -189472 -14.45% 2019-03-31
iShares Nasdaq Biotechnology ETF 1491138 0.99% 26767 1.83% 2019-07-30
Meridian Small Cap Growth Fund 1523553 1.02% -169439 -10.01% 2019-03-31
Vanguard Extended Market Index Fund 2090792 1.39% -5225 -0.25% 2019-06-30
PrimeCap Odyssey Growth Fund 2400000 1.60% -- -- 2019-06-30
iShares Russell 2000 ETF 3271748 2.18% 6402 0.20% 2019-07-30
Vanguard Total Stock Market Index Fund 3290639 2.20% 561716 20.58% 2019-06-30
SPDR 10082534 6.73% -9868 -0.10% 2019-06-21
Direxion Daily S&P Biotech Bull 3X Shrs 991917 0.66% 269152 37.24% 2019-04-30
Candriam Eqs L Biotechnology 912500 0.61% -100000 -9.88% 2019-06-30
NT R2000 Growth Index Fund - Non-Lending 589034 0.39% -32493 -5.23% 2019-06-30
iShares Russell 2000 Value ETF 589760 0.39% 1194 0.20% 2019-07-31
State Street Russell Small Cap 600952 0.40% -- -- 2019-07-31
State Street Russell Small/Mid Cap 649698 0.43% 48800 8.12% 2019-07-31
iShares Russell 2000 Growth ETF 724343 0.48% -- -- 2019-07-30
Vanguard Explorer Fund 823076 0.55% -- -- 2019-03-31
Vanguard Strategic Small Cap Equity Fund 854990 0.57% -- -- 2019-03-31
Vanguard Capital Opportunity Fund 863800 0.58% -- -- 2019-03-31
TIAA-CREF Quant Small-Cap Equity Fund 961600 0.64% -15300 -1.57% 2019-05-31
T. Rowe Price New Horizons Fund 656590 0.44% 92090 16.31% 2019-03-31
T. Rowe Price Health Sciences Fund 870241 0.58% 41508 5.01% 2019-03-31
iShares US Small Cap ETF (CAD-Hedged) 2914220 1.95% -4887 -0.17% 2019-05-30
PGIM Jennison Health Sciences Fund 720106 0.48% -- -- 2019-04-30
Meridian Contrarian Fund 675000 0.45% 675000 -- 2018-12-31
Delaware Healthcare Fund 650000 0.44% -- -- 2019-01-31
Voya SmallCap Opportunities Fund 656815 0.44% 157922 31.65% 2018-09-30
Parvest Equity USA Small Cap 659329 0.44% -5795 -0.87% 2018-11-30
American Funds SMALLCAP World Fund 5433000 3.64% -2000000 -26.91% 2018-09-30
American Funds IS 712570 0.48% -335430 -32.01% 2018-09-30
TIAA-CREF Growth & Income Fund 954482 0.64% -1800 -0.19% 2018-10-31
VA CollegeAmerica SMALLCAP Wld Fd 5433000 3.64% -2000000 -26.91% 2018-09-30
Franklin Biotechnology Discovery Fund 1076400 0.72% -- -- 2018-06-30
iShares Nasdaq Biotechnology 1692315 1.04% -3222 -0.19% 2018-09-12
Vanguard Explorer Inv 823076 0.55% -440515 -34.86% 2018-06-30
T. Rowe Price New Horizons 846900 0.57% 89800 11.86% 2018-06-30
Fidelity VIP Mid Cap Inv 886500 0.59% 886500 -- 2018-07-31
Vanguard Capital Opportunity Inv 898300 0.60% -- -- 2018-06-30
VA CollegeAmerica Smcap World 529E 7433000 4.99% 7433000 -- 2018-06-30
Vanguard Total Stock Mkt Idx 3661203 2.46% -- -- 2018-07-31
PRIMECAP Odyssey Growth 2400000 1.61% -- -- 2018-06-30
Vanguard Extended Market Idx Inv 1942570 1.30% 7500 0.39% 2018-07-31
iShares Russell 2000 Growth 1263014 0.78% -1218 -0.10% 2018-09-12
Delaware Healthcare A 1130000 0.76% -- -- 2018-07-31
CREF Stock R1 1123254 0.75% -6913 -0.61% 2018-07-31
Vanguard Strategic Small-Cap Equity Inv 905546 0.61% -- -- 2018-06-30
Fidelity Advisor 951156 0.64% -1639103 -63.28% 2018-07-31
TIAA-CREF Growth & Income Instl 976082 0.65% -4700 -0.48% 2018-07-31
TIAA-CREF Small-Cap Equity Instl 1017500 0.68% 68700 7.24% 2018-07-31
Vanguard Strategic Equity Inv 1008030 0.68% 308396 44.08% 2018-06-30
Prudential Jennison Health Sciences A 720106 0.48% -- -- 2018-07-31
Fidelity Spartan 658917 0.44% 200313 43.68% 2018-06-30
Franklin Biotechnology Discovery A 660600 0.44% -- -- 2018-06-30
Met Invt Ser ClearBridge Agrsv Gr E 499700 0.38% -- -- 2018-03-31
Schwab US Small-Cap ETF 392029 0.30% -- -- 2018-07-05
Vanguard VIF Small Co Gr 384630 0.29% -66642 -14.77% 2018-03-31
PowerShares Dynamic Biotech & Genome ETF 620370 0.45% -- -- 2018-05-24
PRIMECAP Odyssey Aggressive Growth 325000 0.24% -- -- 2018-03-31
TFS Market Neutral 512563 0.59% 512563 -- 2016-10-31
Vanguard Market Neutral I 320800 0.37% -- -- 2016-09-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 219107 0.25% 21189 10.71% 2016-12-31
Vanguard Health Care ETF 174937 0.20% -540 -0.31% 2016-12-31
Schwab Total Stock Market Index 174500 0.20% -- -- 2016-12-31
PrimeCap Odyssey Aggressive Growth Fund 3857750 4.40% -- -- 2015-09-30
Pictet-Biotech 1862712 2.30% -550322 -22.80% 2014-09-30
SPDR® S&P Biotech ETF 1775008 2.40% 5576 0.30% 2015-11-27
Vanguard Small Cap Index 1705105 2.00% 20962 1.20% 2015-10-31
Legg Mason CB US Aggressive Growth 1509290 1.70% -- -- 2015-10-31
iShares Russell 2000 (AU) 1412096 1.90% -867 -0.10% 2015-11-27
Fidelity Advisor® Biotechnology Fund 1249451 1.40% 67124 5.70% 2015-10-31
Vanguard Small Cap Growth Index Fund 1039887 1.20% -17914 -1.70% 2015-10-31
Vanguard US Opportunities 988679 1.10% -- -- 2015-07-31
Fidelity® Select Biotechnology Portfolio 4827278 5.50% 224224 4.90% 2015-10-31

Daniel M. Junius Mr. Daniel M. Junius is an Independent Director at GlycoMimetics, Inc., an Independent Director at IDEXX Laboratories, Inc., a Chief Financial Officer at Deluxepinpoint Co. and a Treasurer & Director at Biotechnology Innovation Organization. He is on the Board of Directors at GlycoMimetics, Inc., IDEXX Laboratories, Inc., ImmunoGen, Inc. and Biotechnology Innovation Organization. Mr. Junius was previously employed as a Chief Financial Officer & Executive Vice President by New England Business Service, Inc. and a Chief Financial Officer & Vice President by Nashua Corp. He also served on the board at Vitae Pharmaceuticals, Inc. He received his undergraduate degree from Boston College and a graduate degree from Kellogg School of Management.
Howard H. Pien Mr. Howard H. Pien is Chairman at Indivior Plc, Non-Executive Chairman at Juno Therapeutics, Inc., Chairman at Reckitt Benckiser Pharmaceuticals, Inc. and Chairman at Sapience Therapeutics, Inc. He is on the Board of Directors at ImmunoGen, Inc. Mr. Pien was previously employed as an Independent Director by SAGE Therapeutics, Inc., a Lead Independent Director by Ikaria, Inc., a Lead Independent Director by ViroPharma, Inc., Chairman, President & Chief Executive Officer by Medarex, Inc., an Independent Director by Vanda Pharmaceuticals, Inc., President, Chief Executive Officer & Director by Chiron Corp., a Lead Independent Director by ViroPharma, Inc., President-Pharmaceuticals International by GlaxoSmithKline Plc, a Principal by Abbott Laboratories, Vice President by Merck & Co., Inc., and President-Pharmaceuticals Operations by Smithkline Beecham Plc. He also served on the board at Talon Therapeutics, Inc., Arresto BioSciences, Inc., Bellerophon Therapeutics, Inc., Biotechnology Innovation Organization, Childrens Hospital Oakland, Pharmaceutical Research & Manufacturers of America, The Fox Chase Cancer Center, UCSF Benioff Children's Hospital Oakland and ViroPharma, Inc. He received his undergraduate degree from Massachusetts Institute of Technology and an MBA from Carnegie Mellon University.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐